Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; Division of Gastroenterology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Curr Opin Pharmacol. 2017 Dec;37:65-71. doi: 10.1016/j.coph.2017.09.007. Epub 2017 Oct 6.
For the ultimate aim of preventing intestinal disability in inflammatory bowel disease (IBD), the treatment goal has moved from symptom control towards inflammation control (i.e., 'deep remission'). Furthermore, the concept of 'treat-to-target' has been adopted to assist in treatment escalation and better control. Although deep remission is possible with current biologics, there are still unmet needs in IBD management. Biosimilars of several biologics will be an increasingly common option in the near future. In this review, we review the current status of novel drugs for IBD, focusing on recent phase 2 and 3 randomized controlled trials, and address the issues of biosimilars. Recent studies of the 'treat-to-target' strategy and therapeutic drug monitoring are summarized.
为了预防炎症性肠病（IBD）中的肠道残疾这一终极目标，治疗目标已经从症状控制转向炎症控制（即“深度缓解”）。此外，还采用了“靶向治疗”的概念来辅助治疗升级和更好的控制。尽管目前的生物制剂可以实现深度缓解，但 IBD 的管理仍存在未满足的需求。几种生物制剂的生物类似药在不久的将来将成为越来越常见的选择。在这篇综述中，我们回顾了 IBD 的新型药物的现状，重点介绍了最近的 2 期和 3 期随机对照试验，并讨论了生物类似药的问题。总结了最近关于“靶向治疗”策略和治疗药物监测的研究。
